MCL

Delta Health leveraged their relationship with Mayo Clinic Laboratories to support patient in rural Colorado during the COVID-19 pandemic. Delta Health and Mayo Clinic Laboratories have collaborated for over 17 years to perform complex and esoteric testing.

For patients with chronic lymphocytic leukemia (CLL) — the most common leukemia in adults — advanced testing can not only provide valuable information about their disease state, but peace of mind in the face of a progressive, incurable illness. Oftentimes, however, complex molecular and genetic tests to identify biomarker cues about disease trajectory and treatment intolerance are not performed, putting patients at risk for unmet expectations and unsatisfactory outcomes.

This "Pathways" program provides Anatomic and Clinical Pathology cases that include a history, potential answers, rationale, and relevant references. Cases for June include the following sub-specialties: Bone and Soft Tissue Pathology, Gastroenterology Pathology, Gynecological Pathology, Hematopathology, and Laboratory Genetics and Genomics.

The genetic variability of glioma, and its more advanced relative glioblastoma, has made genetic testing to identify biomarkers associated with prognosis and treatment effectivity an integral component of care plan development. However, the acceleration of brain tumor research and discovery translates into an ever-changing testing environment.

Kevin Halling, M.D., Ph.D., explains how the MayoComplete Solid Tumor panel uses next-generation sequencing to assess 514 clinically significant, cancer-related genes for genetic alterations that offer insight on treatment effectivity.

A collaborative study between Mayo Clinic and the University of Illinois debunked the previous consensus about how kidney stones grow.

Part II of this series shows how a breakthrough discovery about how kidney stones form may open the way for new, unorthodox treatments. The discovery was made possible by joining University of Illinois’ geology and biology forces with Mayo Clinic’s urology and nephrology expertise.

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, hosts this episode of the "Answers From the Lab" podcast. He’s joined by Gianluca Pettiti, senior vice president and president of specialty diagnostics at Thermo Fisher Scientific to discuss their organizations’ collaboration and its value for patients.

When most of the world was still struggling to understand how COVID-19 would affect their lives, Atria Senior Living took steps to protect their vulnerable residents and staff.

In this month’s “Hot Topic,” Andrew McKeon, M.B., B.Ch., M.D., reviews the use of neurological phenotype-based evaluations, the move away from the paraneoplastic evaluation, and upcoming changes to test profiles.

In this episode, Vlad Vasile, M.D., Ph.D., assistant professor of Laboratory Medicine and Pathology and cardiologist at Mayo Clinic, discusses cardiovascular risk testing, including biomarkers and clinical implications.

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update. In this episode, Dr. Morice and Bobbi Pritt, M.D., discuss the future of laboratory medicine in a post-pandemic world.

This "Pathways" program provides Anatomic and Clinical Pathology cases that include a history, potential answers, rationale, and relevant references. Cases for May include the following sub-specialties: Bone and Soft Tissue Pathology, Genitourinary Pathology, Gynecological Pathology, Hematopathology, and Surgical Pathology.